MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dyne Therapeutics
DYN
|
+$15.9M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
+$15.4M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$13.7M |
| 4 |
Rocket Pharmaceuticals
RCKT
|
+$11.6M |
| 5 |
DBV Technologies S.A. American Depositary Shares
DBVT
|
+$9.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lantheus
LNTH
|
+$22.7M |
| 2 |
United Therapeutics
UTHR
|
+$18.2M |
| 3 |
iTeos Therapeutics
ITOS
|
+$10.4M |
| 4 |
Twist Bioscience
TWST
|
+$10.3M |
| 5 |
Natera
NTRA
|
+$9.06M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$728M
| $57.6M | 9.98% |
7,648,268
| – | – |
2021 Q1
17 quarters
|
|
2
Madrigal Pharmaceuticals
MDGL
$9.28B
| $30.4M | 5.27% |
100,415
| – | – |
2025 Q1
1 quarter
|
|
3
Zai Lab
ZLAB
$3.15B
| $26.1M | 4.51% |
745,060
-88,599
| -11% | -$2.91M |
2024 Q4
2 quarters
|
|
4
Guardant Health
GH
$20.4B
| $23M | 3.99% |
442,656
| – | – |
2024 Q2
4 quarters
|
|
5
ARS Pharmaceuticals
SPRY
$280M
| $22.7M | 3.94% |
1,303,399
-9,705
| -0.7% | -$140K |
2025 Q1
1 quarter
|
|
6
Edgewise Therapeutics
EWTX
$4.93B
| $22.6M | 3.91% |
1,720,741
+615,297
| +56% | +$8.87M |
2024 Q1
5 quarters
|
|
|
RNAM
7
DELISTED
Avidity Biosciences
RNAM
| $21.6M | 3.74% |
760,022
+45,798
| +6% | +$1.37M |
2024 Q2
4 quarters
|
|
8
PTC Therapeutics
PTCT
$5.47B
| $21.4M | 3.71% |
438,477
-1,500
| -0.3% | -$71.2K |
2024 Q3
3 quarters
|
|
9
Trevi Therapeutics
TRVI
$2.04B
| $18.6M | 3.23% |
3,406,955
-21,411
| -0.6% | -$133K |
2024 Q1
5 quarters
|
|
10
Oric Pharmaceuticals
ORIC
$914M
| $17.6M | 3.04% |
1,729,378
+329,864
| +24% | +$2.21M |
2025 Q1
1 quarter
|
|
|
11
Natera
NTRA
$45B
| $16.7M | 2.9% |
98,924
-58,123
| -37% | -$9.06M |
2024 Q1
5 quarters
|
|
12
Alkermes
ALKS
$7.71B
| $15.7M | 2.72% |
549,262
+211,659
| +63% | +$6.3M |
2025 Q1
1 quarter
|
|
13
MoonLake Immunotherapeutics
MLTX
$981M
| $14.8M | 2.56% |
313,571
-2,478
| -0.8% | -$101K |
2023 Q2
8 quarters
|
|
14
MBX Biosciences
MBX
$2.47B
| $14.8M | 2.56% |
1,294,416
+161,466
| +14% | +$1.64M |
2025 Q1
1 quarter
|
|
15
Compass Therapeutics
CMPX
$137M
| $14.6M | 2.53% |
5,622,505
-2,820,278
| -33% | -$5.82M |
2024 Q1
5 quarters
|
|
16
Ultragenyx Pharmaceutical
RARE
$1.57B
| $14.4M | 2.49% |
395,700
-2,745
| -0.7% | -$99K |
2024 Q1
5 quarters
|
|
17
Janux Therapeutics
JANX
$1.08B
| $14.2M | 2.46% |
614,282
+47,089
| +8% | +$1.24M |
2024 Q3
3 quarters
|
|
|
18
Tarsus Pharmaceuticals
TARS
$3.38B
| $13.8M | 2.4% |
+341,496
| New | +$15.4M |
2025 Q2
0 quarters
|
|
|
19
Dyne Therapeutics
DYN
$3.39B
| $13.8M | 2.39% |
+1,446,361
| New | +$15.9M |
2025 Q2
0 quarters
|
|
20
Vera Therapeutics
VERA
$2.15B
| $13.3M | 2.3% |
563,075
+147,356
| +35% | +$3.31M |
2024 Q4
2 quarters
|
|
21
DELISTED
Crinetics Pharmaceuticals
CRNX
| $12.3M | 2.14% |
428,975
-202,989
| -32% | -$6.27M |
2021 Q3
15 quarters
|
|
22
Revolution Medicines
RVMD
$41.6B
| $11.6M | 2.01% |
315,722
-1,361
| -0.4% | -$52.3K |
2021 Q3
15 quarters
|
|
23
Akebia Therapeutics
AKBA
$111M
| $10.5M | 1.82% |
+2,889,125
| New | +$7.94M |
2025 Q2
0 quarters
|
|
24
Olema Pharmaceuticals
OLMA
$641M
| $10.1M | 1.76% |
2,378,762
-551,684
| -19% | -$2.46M |
2023 Q2
8 quarters
|
|
25
Xenon Pharmaceuticals
XENE
$3.79B
| $10.1M | 1.75% |
323,398
+20,000
| +7% | +$652K |
2024 Q3
3 quarters
|
|
Similar funds
MPM BioImpact's Q2 2025 Portfolio in Review
As of Q2 2025, MPM BioImpact held 51 positions worth $577M, down 0.78% from $582M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
MPM BioImpact's Q2 2025 filing shows 8 new, 10 increased, 20 reduced and 7 closed positions. Its largest new stake was Dyne Therapeutics: 1,446,361 shares worth $13.8M. The largest sale was Lantheus, an estimated $22.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- MPM BioImpact's largest Q2 2025 buy was Dyne Therapeutics: 1,446,361 shares worth $13.8M.
- MPM BioImpact added most to Rocket Pharmaceuticals in Q2 2025, an estimated $11.6M increase.
- MPM BioImpact's biggest Q2 2025 reduction was Natera, cutting an estimated $9.06M.
- MPM BioImpact fully exited Lantheus in Q2 2025, selling an estimated $22.7M.
- MPM BioImpact's ten largest holdings make up 45% of its $577M portfolio in Q2 2025.
- MPM BioImpact opened 8 new positions and closed 7 in Q2 2025.
- MPM BioImpact's portfolio value fell 0.78% quarter-over-quarter to $577M.
Based on MPM BioImpact's 13F filing for Q2 2025, filed 14 Aug 2025.